All In Biotech

Drug Trial Radar · NCT00348348

A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis

Last checked: Nov 20, 2026Latest source record: Mar 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,161

Actual

Start

Jun 2006

Primary completion

Jul 2007

Study completion Jul 2007

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Jul 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to investigate a novel drug candidate for the treatment of bacterial conjunctivitis.

Conditions

  • Acute Bacterial Conjunctivitis

Interventions

  • BesifloxacinDrug

    Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days

  • Moxifloxacin solutionDrug

    Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical ResolutionTime frame: Day 5(+/- 1 day)
  2. Microbial EradicationTime frame: Day 5 (+/- 1 day)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.